Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx Ocular UK
Botaretigene sparoparvovec is an AAV5 viral vector gene therapy carrying the RPGR gene, delivered subretinally to the eye. It is being studied in X-linked retinitis pigmentosa.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04794101 | Phase 3 | X-Linked Retinitis Pigmentosa | Active not recruiting | MGTX |
| NCT06646289 | Phase 2 | X-Linked Retinitis Pigmentosa | Active not recruiting | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
X-Linked Retinitis Pigmentosa
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →